AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Recursion Pharmaceuticals vs Nabla

Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.

Recursion Pharmaceuticals

Recursion Pharmaceuticals

VS
Nabla

Nabla

Verdict by Category

AI content generation failed. Refresh the page to try again.
View Recursion Pharmaceuticals View Nabla

Detailed Comparison

Feature
Recursion Pharmaceuticals
Nabla
Pricing
CustomRecursion operates through three revenue streams: pharma collaboration agreements, data licensing, and its own internal drug pipeline. Pharma partnerships (Roche/Genentech, Sanofi) are structured as multi-year agreements with upfront payments and milestone-based payments tied to program progress. Recursion has earned $500M+ in cumulative milestones to date, with $134M from Sanofi alone. Data licensing allows external researchers and pharma companies to access Recursion's proprietary biology maps and phenomics datasets for their own target discovery programs. Recursion's own clinical programs (REC-4881, REC-1245, REC-4539) will generate revenue through future partnering, co-development, or commercialization deals as they advance through clinical trials. Total 2025 revenue: $74.7M. Contact Recursion through recursion.com for partnership inquiries.
FreemiumNabla does not publish exact pricing on its official website; the primary calls-to-action are a free trial (via app.nabla.com) and "Talk to our team" for enterprise sales. Third-party sources consistently report a free tier with usage limits, with paid individual/clinician plans starting around $119/month per provider and higher tiers reported near $239/month per provider. Larger health-system deployments — Nabla's core market, spanning 130+ organizations — are sold via custom enterprise contracts with volume-based pricing, with independent estimates placing typical enterprise rates in the $150-$400/month per provider range depending on scale, EHR integration depth, and features. Exact costs require a sales conversation with Nabla.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
AI-native drug discovery OS with industrial-scale automated labs and $500M+ in pharma partnerships
Ambient AI that turns patient visits into clinical notes, dictation, and coding — right inside the EHR
Recursion Pharmaceuticals

Recursion Pharmaceuticals Pros & Cons

Pros

  • $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
  • Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
  • Industrial-scale automated labs generate data no other company can replicate
  • Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
  • Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
  • Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
  • Cash runway guided into early 2028 — disciplined capital allocation

Cons

  • Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
  • Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
  • Acquired Exscientia in 2024 — integration complexity and added operational overhead
  • No approved drugs yet — clinical proof of concept still early stage
  • Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Nabla

Nabla Pros & Cons

Pros

  • Fast note generation, roughly five seconds, that closely mirrors real clinical documentation in independent tests
  • Deep native integration with Epic and other major EHRs rather than copy-paste workflows
  • Broad specialty and language coverage suited to large, diverse health systems
  • Strong compliance posture (HIPAA, SOC 2 Type 2, ISO 27001, GDPR) with configurable data retention
  • Backed by peer-reviewed evidence, including a NEJM AI randomized trial showing documentation-time reductions
  • Combines documentation, dictation, and coding in one platform instead of separate point tools

Cons

  • Pricing isn't published; individuals and smaller practices must go through a sales conversation or rely on third-party estimates to budget
  • Primarily built for hospitals and health systems, so solo clinicians and small practices may find it less tailored than SMB-focused scribes
  • Relies on ambient recording, so encounters where a patient or clinician can't or won't be recorded aren't well supported
  • Some independent reviews note limited customization and quality drop-off on complex, multi-problem visits
  • Mobile app store ratings are mixed and based on a relatively small number of reviews compared to the platform's overall clinician base